<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67449">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02227771</url>
  </required_header>
  <id_info>
    <org_study_id>BSC-03</org_study_id>
    <nct_id>NCT02227771</nct_id>
  </id_info>
  <brief_title>Consistent CTO Trial</brief_title>
  <official_title>CONventional Antegrade vs Sub-Intimal Synergy sTENTing in Chronic Total Occlusions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Cardiovascular Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ceric Sàrl</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>European Cardiovascular Research Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that enhanced vascular healing with the Synergy
      stent should minimize the risk of late aneurysm formation and potential clinical
      complications but not at the cost of enhanced efficacy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary stent endpoint is 12-month target vessel failure (TVF) rate</measure>
    <time_frame>12 months</time_frame>
    <description>The primary stent endpoint is 12-month target vessel failure (TVF) rate, defined as any ischemia-driven revascularization of the target vessel, MI (Q-wave and non-Q-wave) related to the target vessel or cardiac death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization (TLR) rate</measure>
    <time_frame>In hospital, 6 Months, 12 Months, 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure (TLF) rate</measure>
    <time_frame>In hospital, 6 Months, 12 Months, 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization (TVR) rate</measure>
    <time_frame>In hospital, 6 Months, 12 Months, 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure (TVF) rate</measure>
    <time_frame>In hospital, 6 Months, 12 Months, 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction (MI, Q-wave and non-Q-wave) rate</measure>
    <time_frame>In hospital, 6 Months, 12 Months, 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death rate</measure>
    <time_frame>In hospital, 6 Months, 12 Months, 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-cardiac death rate</measure>
    <time_frame>In hospital, 6 Months, 12 Months, 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All death rate</measure>
    <time_frame>In hospital, 6 Months, 12 Months, 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death or MI rate</measure>
    <time_frame>In hospital, 6 Months, 12 Months, 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All death or MI rate</measure>
    <time_frame>In hospital, 6 Months, 12 Months, 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All death/MI/TVR rate</measure>
    <time_frame>In hospital, 6 Months, 12 Months, 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis rate (by ARC definitions)</measure>
    <time_frame>In hospital, 6 Months, 12 Months, 2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angina, dyspnoea and quality of life scores</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-segment percent diameter stenosis (%DS)</measure>
    <time_frame>Peri-procedural</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-segment minimum lumen diameter (MLD)</measure>
    <time_frame>Peri-procedural</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute gain</measure>
    <time_frame>Peri-procedural</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-segment %DS</measure>
    <time_frame>12-Months Post-Index Procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-segment late loss</measure>
    <time_frame>12-Months Post-Index Procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-segment binary restenosis rate</measure>
    <time_frame>12-Months Post-Index Procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-segment MLD</measure>
    <time_frame>12-Months Post-Index Procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incomplete apposition</measure>
    <time_frame>Peri-procedural</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent, vessel and lumen areas and volumes</measure>
    <time_frame>Peri-procedural</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incomplete apposition</measure>
    <time_frame>12-Months Post-Index Procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aneurysm formation</measure>
    <time_frame>12-Months Post-Index Procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial strut coverage percentage</measure>
    <time_frame>12-Months Post-Index Procedure</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">215</enrollment>
  <condition>Chronic Total Occlusion</condition>
  <arm_group>
    <arm_group_label>Patient with chronic total occlusion</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous coronary intervention</intervention_name>
    <arm_group_label>Patient with chronic total occlusion</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who come to hospital for CTO and who met all the inclusion/eclusion criteria
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patient &gt;18 years old

          -  Females of childbearing potential with a negative pregnancy test

          -  Presence of Chronic Total Occlusion (CTO) that is known or presumed to be of at least
             3 months in duration

          -  Subject (or legal guardian) understands the trial requirements and the treatment
             procedures and provides written informed consent

          -  Attempt to implant at least one Synergy II stent has been made

        Exclusion Criteria:

          -  Acute myocardial infarction with ongoing ST-elevation

          -  Cardiogenic shock

          -  Left ventricular ejection fraction &lt;20%

          -  Subject has one of the following (as assessed prior to the index procedure):

        Other serious medical illness (e.g., cancer, congestive heart failure) with estimated life
        expectancy of less than 24 months Current problems with substance abuse (e.g., alcohol,
        cocaine, heroin, etc.) Planned procedure that may cause non-compliance with the protocol
        or confound data interpretation

          -  Subject is treated by dialysis or has a baseline serum creatinine level &gt;220 μmol/L
             (2.5 mg/dL)

          -  Known allergy to to contrast (that cannot be adequately premedicated) and/or the
             trial stent system or protocol-required concomitant medications (e.g., platinum,
             platinum-chromium alloy, stainless steel, everolimus or structurally related
             compounds, polymer or individual components, all P2Y12 inhibitors, or aspirin)

          -  Subject is participating in another investigational drug or device clinical trial
             that has not reached its primary endpoint OR subject intends to participate in
             another investigational drug or device clinical trial within 12 months after the
             index procedure

          -  Need for ongoing long-term anticoagulation

          -  Subject has received an organ transplant or is on a waiting list for an organ
             transplant

          -  Subject is receiving or scheduled to receive chemotherapy within 30 days before or
             after the index procedure

          -  Planned CABG after the index procedure

          -  Subject previously treated at any time with intravascular brachytherapy

          -  Subject has a platelet count &lt;100,000 cells/mm3 or &gt;700,000 cells/mm3

          -  Subject has a white blood cell (WBC) count &lt; 3,000 cells/mm3

          -  Subject has documented or suspected liver disease, including laboratory evidence of
             hepatitis

          -  Subject has a clinically significant bleeding diathesis or coagulopathy or will
             refuse blood transfusions

          -  Subject has had a history of cerebrovascular accident (CVA) or transient ischemic
             attack (TIA) within the past 6 months

          -  Subject has an active peptic ulcer or active gastrointestinal (GI) bleeding

          -  Subject has severe symptomatic heart failure (i.e., NYHA class IV)

          -  Subject with known intention to procreate within 12 months after the index procedure
             (women of child-bearing potential who are sexually active must agree to use a
             reliable method of contraception from the time of screening through 12 months after
             the index procedure)

          -  Subject is a woman who is pregnant or nursing (a pregnancy test must be performed
             within 7 days prior to the index procedure in women of child-bearing potential)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Simon Walsh, Dr</last_name>
    <phone>+442895048229</phone>
    <email>simon.walsh@belfasttrust.hscni.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Belfast Health &amp; Social Care Trust</name>
      <address>
        <city>Belfast</city>
        <zip>BT9 7AB</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colm Hanratty, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Colm Hanratty, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Infirmary</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8HW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julian Strange, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Julian Stange, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Edinburgh Royal Infirmary</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Spratt, Dr</last_name>
    </contact>
    <investigator>
      <last_name>James Spratt, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee, Glasgow</name>
      <address>
        <city>Glasgow</city>
        <zip>G81 4DY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keith Oldroyd, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Keith Oldroyd, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Chest Hospital,</name>
      <address>
        <city>London</city>
        <zip>E2 9JX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elliot Smith, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Elliot Smith, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kings College, London</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Hill, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Jonathan Hill, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Ireland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 16, 2016</lastchanged_date>
  <firstreceived_date>August 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
